Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxercalciferol Injection in Hemodialysis Patients with Secondary Hyperparathyroidism
CTR20211616Phase 3Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of doxercalciferol in secondary hyperparathyroidism (SHPT), chronic kidney disease (CKD), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Aug 2021; status: completed.
02
Drugs
doxercalciferol
03
Conditions
secondary hyperparathyroidism (SHPT)chronic kidney disease (CKD)
Beyond the preview
Go deeper on CTR20211616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211616.